Compare American Tower Corp (AMT) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Tower Corp vs Crispr Therapeutics AG — how do they compare? American Tower Corp trades at $169 (market cap $78.54B), while Crispr Therapeutics AG trades at $53.25 (market cap $5.25B). The key difference: American Tower Corp is far larger — about 15× Crispr Therapeutics AG's market cap, and American Tower Corp pays a 4.14% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| AMT | CRSP | |
|---|---|---|
Market Cap | $78.54B | $5.25B |
Sector | Real Estate | Health |
52-Week High | $232.35 | $76.78 |
52-Week Low | $162.11 | $44.34 |
Enterprise Value | $122.07B | $3.60B |
Dividend Yield | 4.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower (AMT) trades at $168.59, up 2.18% today, with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals including a 26.81% net margin and 82.19% ROE. Recent news highlights its data center growth and sustainability initiatives, while analyst consensus remains strongly bullish with a $214.10 price target.
AMT presents a compelling long-term investment opportunity given its high profitability, dividend yield, and market leadership, though elevated debt levels and near-term technical weakness pose risks. Upside potential exists if the company continues executing on 5G and data center expansion, but investors should monitor interest rate sensitivity and competitive pressures.
CRISPR Therapeutics (CRSP) trades at $53.35, down 5.31% on the day, with technical indicators showing a bullish trend but mixed earnings performance. The company maintains strong analyst support with a $74.50 consensus price target, despite negative profitability metrics and recent quarterly misses. Recent FDA pediatric approval for Casgevy expands its market potential, though cash flow remains challenged by high operational costs.
Outlook is cautiously optimistic driven by gene-editing leadership and clinical catalysts, but investment carries high risk due to persistent losses, volatile cash flows, and competitive pressures. Upside depends on successful commercialization and pipeline execution, while downside risks include funding needs and regulatory hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
